You can buy or sell AXNX and other stocks, options, ETFs, and crypto commission-free!
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Read More It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.
52 Week High
52 Week Low
Yahoo FinanceApr 24
Axonics® to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the first quarter of 2019 and provide an update on operations and FDA regulatory status after the market closes on Wednesday, May 8, 2019. In conjunction with the release, the Compa...
-$0.47 per share